EUVIMEDEUVIMED entdecken
Crossref

Effectiveness and safety of plasma exchange for anti‐MDA5 antibody–positive clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease refractory to intensive immune suppression therapy: A case series

Tomoka Watanabe, Misaki Taniguchi, Sanae Ogura, Mea Asou, Shunsuke Takayanagi, Yuko Sokai, Yoshiki Tsuji, Keita P Mori, Tomomi Endo, Toshiki Nakajima, Yoshitaka Imura, Tatsuo Tsukamoto iD

Therapeutic Apheresis and Dialysis · 2024-06 · 28 (3) · 432-441

DOI: 10.1111/1744-9987.14106 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Apheresis and Dialysis, online erschienen am 15.01.2024. Verfasst von Tomoka Watanabe und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology and Dialysis, Medical Research Institute Kitano Hospital, PIIF Tazuke-Kofukai, Osaka, Japan. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Dermatomyositis, Plasma Exchange, Interferon-Induced Helicase, IFIH1. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Clinically amyopathic dermatomyositis (CADM) with anti‐melanoma differentiation‐associated gene 5 (MDA5) antibody (Ab) with rapidly progressive interstitial lung disease (RP‐ILD) is often refractory for intensive immunosuppression. In this study, we verified the effectiveness and safety of plasma exchange (PEx) for this lethal disease.

Methods

We retrospectively examined the clinical course and adverse effect (AE) of 12 patients with anti‐MDA5 Ab–positive CADM between January 2017 and December 2021 in our hospital.

Results

Five out of six patients treated with simple PEx using fresh frozen plasma or 5% albumin survived with or without home oxygen therapy. Multiple PEx (15–20 times) were required to achieve satisfactory improvement as well as remission of CADM. The AEs caused by PEx were resolved using conventional methods.

Conclusion

PEx might be a promising option for controlling the disease activity of anti‐MDA5 Ab–positive CADM with severe RP‐ILD and may contribute to better survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung Diseases, InterstitialDermatomyositisPlasma ExchangeInterferon-Induced Helicase, IFIH1HumansMaleFemaleMiddle AgedRetrospective StudiesAdultAgedTreatment OutcomeDisease ProgressionAutoantibodies

Stichwörter der Autor:innen

anti‐MDA5 antibodycase seriesclinically amyopathic dermatomyositisinterstitial lung diseaseplasma exchange

Substanzen

Interferon-Induced Helicase, IFIH1IFIH1 protein, humanAutoantibodies

Autor:innen und Institutionen

  • Department of Nephrology and Dialysis, Medical Research Institute Kitano Hospital, PIIF Tazuke-Kofukai, Osaka, Japan.
  • Department of Clinical Engineering, Medical Research Institute Kitano Hospital, PIIF Tazuke-Kofukai, Osaka, Japan.
  • Department of Immunology, Medical Research Institute Kitano Hospital, PIIF Tazuke-Kofukai, Osaka, Japan.

ORCID-Profile: Tatsuo Tsukamoto

Zitieren

APA

Watanabe, T., Taniguchi, M., Ogura, S., Asou, M., Takayanagi, S., Sokai, Y., Tsuji, Y., Mori, K. P., Endo, T., Nakajima, T., Imura, Y., & Tsukamoto, T. (2024). Effectiveness and safety of plasma exchange for anti‐MDA5 antibody–positive clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease refractory to intensive immune suppression therapy: A case series. Therapeutic Apheresis and Dialysis, 28(3), 432-441. https://doi.org/10.1111/1744-9987.14106

Vancouver

Watanabe T, Taniguchi M, Ogura S, Asou M, Takayanagi S, Sokai Y, et al. Effectiveness and safety of plasma exchange for anti‐MDA5 antibody–positive clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease refractory to intensive immune suppression therapy: A case series. Therapeutic Apheresis and Dialysis. 2024;28(3):432-441. doi:10.1111/1744-9987.14106

BibTeX
@article{Watanabe2024,
  author = {Watanabe, Tomoka and Taniguchi, Misaki and Ogura, Sanae and Asou, Mea and Takayanagi, Shunsuke and Sokai, Yuko and Tsuji, Yoshiki and Mori, Keita P and Endo, Tomomi and Nakajima, Toshiki and Imura, Yoshitaka and Tsukamoto, Tatsuo},
  title = {Effectiveness and safety of plasma exchange for anti‐MDA5 antibody–positive clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease refractory to intensive immune suppression therapy: A case series},
  journal = {Therapeutic Apheresis and Dialysis},
  year = {2024},
  volume = {28},
  number = {3},
  pages = {432--441},
  doi = {10.1111/1744-9987.14106}
}
Kostenlos starten →